As there is no accepted standard treatment for patients with t-MN, other treatment approaches in the same time period of our study varied from supportive care only to low-dose cytarabine, gemtuzumab-ozogamicin in combination with G-CSF and cytarabine, standard induction chemotherapy and front-line allogeneic bone marrow transplantation [30]. Here, CSF3 is linked to therapy-related myeloid neoplasm.